including the etiology of liver cirrhosis and measures of severity of disease, are shown in Table 1. Of these 101 patients, 12 did not have esophageal varices at endoscopy, 43 had small esophageal ...

cirrhosis and portal hypertension. In the pre-specified per-protocol population, the 2 mg/kg dose of belapectin significantly reduced the development of esophageal varices compared to placebo (p 0 ...

Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension. Hepatology 47 , 1595–1603 (2008). Article Google Scholar ...

Lamivudine has been reported to improve liver function and histology, reduce hepatic decompensation and hepatocellular carcinoma, suppress HBV replication, and reverse fibrosis in patients with ...

Esophageal and esophagogastric varices are ... To our knowledge this is a heretofore undescribed source of bleeding in cirrhosis. Case Report A.G. (M.S.H. 317076), a 43-year-old man, was admitted ...

Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40: 652–659. 4. Paquet KJ and Feussner H. Endoscopic sclerosis and esophageal balloon ...

cirrhosis who have clinical signs of portal hypertension and are at risk of developing esophageal varices. Citing data from three patient cohorts who received belapectin 2 mg/kg, belapectin 4 mg ...

Background: It is currently recommended that all patients with liver cirrhosis undergo upper gastrointestinal endoscopy (UGIE) to identify those who have large esophageal varices (LEVx ...